Table 5 Discounted and undiscounted incremental lifetime cost-effectiveness ratio’s, overall and by gender
From: Cost-effectiveness of enzyme replacement therapy for Fabry disease
Discount rate at 1.5% for effects and 4% for costs | Discount rate at 0% for effects and costs | |
|---|---|---|
ALL | ||
Incremental costs per extra year free of end-organ damage | €3,318,239 | €6,560,885 |
Incremental costs per QALY gained | €3,282,252 | €6,065,529 |
MALES | ||
Incremental costs per extra year free of end-organ damage | €2,982,022 | €5,917,091 |
Incremental costs per QALY gained | €2,947,380 | €5,451,797 |
FEMALES | ||
Incremental costs per extra year free of end-organ damage | €3,797,767 | €7,527,013 |
Incremental costs per QALY gained | €3,742,702 | €6,955,612 |